1693734-80-3
1693734-80-3
Chemical Structure
NXP800
Synonym(s): CCT361814
- CAS. Nr.: 1693734-80-3
- Formula:C32H32FN5O4
- Molecular Weight:569.63
IUPAC Name: N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide
InChIKey: UBALMDIKIGDHJW-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C2OCCOC2=C1)NC3=CC=C(C(NC(C4=CC5=C(N=C(CN6CCN(CC6)CC)C=C5)C=C4)=O)=C3)F
Biological Activity: NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NXP800 | 99.86% | NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Keith Jones, et al. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. WO2015049535A1.
- [2]. Pasqua AE, et al. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. J Med Chem. 2023 [Content Brief]
